Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase NA 1

Status

Completed 2

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Leukemia, Myeloid, Acute 54Multiple Myeloma 45Lymphoma 44Lymphoma, Non-Hodgkin 41Leukemia 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Hodgkin Disease 35Myelodysplastic Syndromes 34Lymphoma, Mantle-Cell 20Lymphoma, Large B-Cell, Diffuse 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19Leukemia, Lymphocytic, Chronic, B-Cell 16Burkitt Lymphoma 16Breast Neoplasms 13Neoplasms, Plasma Cell 11Recurrence 10Lymphoma, Follicular 10Hematologic Neoplasms 9Anemia, Refractory, with Excess of Blasts 9Lymphoma, B-Cell, Marginal Zone 8Neuroblastoma 7Myeloproliferative Disorders 7Lymphoma, Large-Cell, Immunoblastic 7Central Nervous System Neoplasms 7Blast Crisis 7Neoplasms 6Lymphoma, T-Cell 6Leukemia, Myelomonocytic, Juvenile 6Leukemia, Myelomonocytic, Chronic 6Graft vs Host Disease 6

Interventions

Sunitinib 64Nivolumab 54Sorafenib 38Bevacizumab 35Axitinib 35pembrolizumab 34Everolimus 30cabozantinib 29pazopanib 26aldesleukin 26Ipilimumab 23Interleukin-2 19Specimen Handling 17Magnetic Resonance Spectroscopy 17Gemcitabine 17lenvatinib 16Interferon-alpha 15Interferon alpha-2 13Radiosurgery 12Cyclophosphamide 12fludarabine phosphate 11atezolizumab 10durvalumab 8Introns 8Erlotinib Hydrochloride 8Biopsy 8temsirolimus 7avelumab 7Radiotherapy 7Capecitabine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Renal Cell × Granulocyte Colony-Stimulating Factor × Clear all
NCT00068393 2023-07-07

Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma

Eastern Cooperative Oncology Group

Phase 2 Completed
39 enrolled 7 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT00393029 2011-08-15

Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡